Company: DMAAR
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001213900-25-076681
Chunk: 20

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 20
---
 Unit consists of one ordinary share and one
right (“Public Right”), with each Public Right entitling the holder to receive one-eighth (1/8) of one ordinary share upon
the consummation of an initial business combination. In connection with the Initial Public Offering, the underwriters were granted a 45-day
option to purchase up to 3,000,000 additional Units to cover over-allotments, if any. On February 18, 2025, the underwriters exercised
their option to purchase an additional 3,000,000 Units at a purchase price of $10.00 per Unit, generating additional gross proceeds of
$30,000,000.

NOTE 4 — PRIVATE PLACEMENT

Simultaneously with the closing of the Initial
Public Offering, the Company consummated the sale of 400,000 Private Placement Units at a price of $10.00 per Private Placement Unit in
a private placement to the Sponsor, for $4,000,000, of which $1,100,000 was not received and included as share subscription receivable.
Since the Initial Public Offering until June 30, 2025, the Sponsor has paid $404,175 in expenses on behalf of the Company (including $50,000
related to the administrative support agreement) affecting the share subscription receivable on the unaudited balance sheet to $695,825.
Each Private Placement Unit consists of one ordinary share and one right to receive one-eighth (1/8) of one ordinary share upon the consummation
of an initial business combination. The proceeds from the sale of the Private Placement Units are added to the net proceeds from
the Initial Public Offering held in the Trust Account. Simultaneously with the sale of the over-allotment option Units on February 18,
2025, the Sponsor purchased an additional 30,000 Private Placement Units at a purchase price of $10.00 per Private Placement Unit, generating
additional gross proceeds of $300,000. If the Company does not complete a Business Combination within the Combination Period, the proceeds
from the sale of the Private Placement Units held in the Trust Account will be used to fund the redemption of the Public Shares (subject
to the requirements of applicable law).

NOTE 5 — RELATED PARTIES

Founder Shares

On June 17, 2024, the Company issued to the
Sponsor an aggregate of 22,361,111 ordinary shares, par value